Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
May 09, 2016 08:38 ET
|
Anthera Pharmaceuticals, Inc.
SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr....
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
April 27, 2016 16:05 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over...
Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
March 10, 2016 08:37 ET
|
Anthera Pharmaceuticals, Inc.
SOLUTION clinical study of oral Sollpura™ enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief...
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
March 07, 2016 08:36 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following...
Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer
January 05, 2016 17:30 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating...
Anthera Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results
November 06, 2015 17:18 ET
|
Anthera Pharmaceuticals, Inc.
Closed $29 million public offering in July including full exercise of underwriters’ option to purchase additional sharesCompleted capsule manufacturing in support of the SOLUTION clinical...
Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial Results
October 28, 2015 15:03 ET
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company’s attendance at the following healthcare conferences: November 4th,...
Anthera Announces Initiation of the SOLUTION Clinical Study of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy of Non-Porcine Origin in People With Cystic Fibrosis
October 02, 2015 12:34 ET
|
Anthera Pharmaceuticals, Inc.
Study to enroll approximately 130 patients with exocrine pancreatic insufficiency
More than 50 clinical sites around the United States and Europe are expected to participate
Anthera to...
Anthera Announces Termination of Blisibimod Partnership in Japan by Zenyaku
September 14, 2015 16:30 ET
|
Anthera Pharmaceuticals, Inc.
Anthera will regain all worldwide rights for blisibimod without cost
No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan
Zenyaku is required to continue...
Anthera Pharmaceuticals Reports 2015 Second Quarter and Operational Update
August 10, 2015 16:01 ET
|
Anthera Pharmaceuticals, Inc.
Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod
Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study...